Evaluation of a tryptase depletion index for better pathologic identification of mast cell activation syndrome
Zeitschrift für Gastroenterologie · 01.03.2023 · 61 (03) · 268-274
DOI: 10.1055/a-1833-9226 ↗Kurz gefasst
Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.03.2023. Verfasst von Tomasz Zienkiewicz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology Bonn-Duisdorf, Bonn, Germany. Hauptthemen laut MEDLINE: Mast Cell Activation Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Background
Laboratory evidence supporting diagnosis of the prevalent condition of mast cell activation syndrome (MCAS) currently includes elevated levels in blood or urine of mediators relatively specific to mast cells (MCs) and/or increased numbers of MCs in luminal gastrointestinal (GI) tract tissues. However, identification of elevated mediators is technically challenging and expensive, and controversy persists regarding the normal ranges of numbers/counts of MCs in various GI tract segments, let alone challenges in determining how many of the visualized MCs are activated. To aid diagnosis of MCAS, we developed a potential new approach for the pathologist to identify the extent of GI tract MC activation easily and inexpensively. Participants and Methods Visualization of MCs in gastrointestinal biopsies from 251 patients vs. 95 controls using antibodies against CD117 and tryptase; MC counting per mm2; calculation of the difference between the CD117-positive MCs (identifying all MCs) vs. tryptase-positive MCs (identifying non-activated tryptase-containing MCs), which we define as the tryptase depletion index (TDI).
Results
Mean total MC counts did not differ significantly between patients and controls, but mean TDIs differed significantly. Non-overlapping confidence intervals at the 99.9% level identified cut-offs of TDIs between patients vs. controls of 26, 45 and 32 MCs/mm2 in gastric antrum, duodenum, and colon, respectively.
Conclusions
The TDI may discriminate between MCAS patients vs. controls. If this preliminary work can be independently confirmed, the TDI may become a useful additional minor diagnostic criterion for MCAS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Pathology Bonn-Duisdorf, Bonn, Germany.
- Division of Internal Medicine, Gemeinschaftskrankenhaus Bonn, Bonn, Germany.
- Institute for Digitalization in General Practice and Center for Rare Diseases Aachen (ZSEA), University Hospital Aachen, Aachen, Germany.
- Center for Bleeding Disorders and Transfusion Medicine (CBT), Bonn, Germany.
- Departments of Medicine, Missouri Baptist Medical Center and Washington University School of Medicine, St. Louis, MO, United States.
- AIM Center for Personalized Medicine, Purchase, NY, United States.
ORCID-Profile: Gerhard J Molderings
Zitieren
APA
Zienkiewicz, T., Homann, J., Mücke, M., Seidel, H., Hertfelder, H. J., Weinstock, L. B., Afrin, L. B., & Molderings, G. J. (2023). Evaluation of a tryptase depletion index for better pathologic identification of mast cell activation syndrome. Zeitschrift für Gastroenterologie, 61(03), 268-274. https://doi.org/10.1055/a-1833-9226
Vancouver
Zienkiewicz T, Homann J, Mücke M, Seidel H, Hertfelder HJ, Weinstock LB, et al. Evaluation of a tryptase depletion index for better pathologic identification of mast cell activation syndrome. Zeitschrift für Gastroenterologie. 2023;61(03):268-274. doi:10.1055/a-1833-9226
BibTeX
@article{Zienkiewicz2023,
author = {Zienkiewicz, Tomasz and Homann, Jürgen and Mücke, Martin and Seidel, Holger and Hertfelder, Hans-Jörg and Weinstock, Leonard B and Afrin, Lawrence B and Molderings, Gerhard J},
title = {Evaluation of a tryptase depletion index for better pathologic identification of mast cell activation syndrome},
journal = {Zeitschrift für Gastroenterologie},
year = {2023},
volume = {61},
number = {03},
pages = {268--274},
doi = {10.1055/a-1833-9226}
}
EUVIMED